Loading…
Loading…
Radiant (Radiant Industries / Radiant Nuclear) is a privately held US company developing Kaleidos, a transportable microreactor rated at about 3 MW thermal / 1 MW electric that fits in a single shipping container. Kaleidos is a high-temperature gas-cooled reactor.
Named counterparties identified by open-source research and written only where a primary source states the relationship — never inferred from sector or co-mention. 1 supplier. This is a partial view: it covers the relationships we could evidence, not the company's full supply base.
Centrus agreed to supply HALEU fuel for Kaleidos commercial units under a multi-year contract, including Radiant prepayments toward Centrus's enrichment capacity buildout; deliveries begin before decade's end. No dollar value or volume share disclosed.
Scope. Absence of a counterparty here is not evidence that none exists — most commercial sourcing is confidential and never becomes public. Rows without a share figure mean no share was disclosed, not that the relationship is small.
Another tracked dossier names this company as a counterparty in its own sourced disclosure — this platform never wrote these rows on this company's own page, they are read here inverted from the dossier that disclosed them. This is a partial view: 990 additional named-counterparty rows across the corpus could not be matched to a tracked dossier by name at all (mostly non-Latin legal names), so the true count is higher than what renders here.
Urenco: 'the signing of an advanced fuels agreement for the supply of high-assay low-enriched uranium (HALEU) to support the deployment of microreactors'; 'the first binding commercial contract by a U.S. advanced reactor developer for Western HALEU enrichment services', to support Radiant's Kaleidos microreactor; signed at the US Embassy in London on 15 September 2025. No volume, value, term or enrichment site (Capenhurst vs Eunice) stated, so no GB>US credit.
Scope. This section is inverted evidence: each linked dossier wrote the original row about itself, describing its own relationship to this company. It is never a claim this company itself disclosed. Absence here is not evidence of no relationship — most of the corpus has no named-counterparty block at all yet.
Every exposure is read as a buyer dependency; the top 3 are its binding chokepoints.
As a buyer, policy pressure across its consumed materials is flat.
Descriptive trend in official policy actions on this company’s materials — a policy-pressure trend, not a price or trading signal. No forward probability is implied. Direction is measured on actions we have discovered, and discovery lags events: where the recent window is too thin to support a calm reading, the row says coverage-limited instead of easing.
No actions in the register have named or swept this company in the last 24 months.